Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describes a sub-study of belantamab mafodotin in combination with nirogacestat for relapsed and refractory multiple myeloma, with the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And Refractory Multiple Myeloma
• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• Nirogacestat (nirogacestat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING